Cost-effectiveness analysis of nebivolol and metoprolol in essential hypertension: A pharmacoeconomic comparison of antihypertensive efficacy of beta blockers

Indian Journal of Pharmacology

Volumn 46, Issue 5, 2014, Pages 485-489

  Patel, Rachna S ^a   Sharma, Kamal H ^b   Kamath, Nitisha A ^c   Patel, Nirav H ^a   Thakkar, Ankita M ^a  

^a Shivrath Centre of Excellence in Clinical Research   (India)

^b UN Mehta Institute for Cardiology and Research Centre   (India)

^c B J MEDICAL COLLEGE   (India)

Author keywords

Cost effectiveness; Hypertension; Metoprolol; Nebivolol; Pharmacoeconomics

Indexed keywords

ANTIHYPERTENSIVE AGENT; BENZOPYRAN DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DELAYED RELEASE FORMULATION; ETHANOLAMINE DERIVATIVE; METOPROLOL; METOPROLOL SUCCINATE; NEBIVOLOL;

ADULT; ANALOGS AND DERIVATIVES; BLOOD PRESSURE; COMPARATIVE STUDY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DELAYED RELEASE FORMULATION; DOSE RESPONSE; DRUG EFFECTS; ECONOMICS; FEMALE; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; PHARMACOECONOMICS; PROSPECTIVE STUDY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ANTIHYPERTENSIVE AGENTS; BENZOPYRANS; BLOOD PRESSURE; COST-BENEFIT ANALYSIS; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; ECONOMICS, PHARMACEUTICAL; ETHANOLAMINES; FEMALE; HUMANS; HYPERTENSION; MALE; METOPROLOL; MIDDLE AGED; PROSPECTIVE STUDIES; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84907542668     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.140577     Document Type: Conference Paper

References (25)

1. Boos CJ, Beevers GD, Lip G Y. Assessment of platelet activation indices using the adviatm 120 amongst 'high-risk' patients with hypertension. Ann Med 2007; 39:72-8.
2. Whitworth JA; World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21:1983-92.
3. Hansson L, Zanchetti A, Carruthers S.G., Dahlof B., Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the hypertension optimal treatment (hot) randomised trial. HOT Study Group. Lancet 1998; 351:1755-62.
4. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: Meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338:b1665.
5. Heidenreich PA, Trogdon JG, Khavjou O.A., Butler J., Dracup K, Ezekowitz MD, et al. American Heart Association Advocacy Coordinating Committee, Stroke Council, Council on Cardiovascular Radiology and Intervention, Council on Clinical Cardiology, Council on Epidemiology and Prevention, Council on Arteriosclerosis, Thrombosis and Vascular Biology, et al. Forecasting the future of cardiovascular disease in the united states: A policy statement from the American heart association. Circulation 2011; 123:933-44.
6. Ormond BA, Spillman BC, Waidmann T.A., Caswell KJ, Tereshchenko B. Potential national and state medical care savings from primary disease prevention. Am J Public Health 2011; 101:157-64.
7. Pittman DG, Tao Z, Chen W., Stettin GD. Antihypertensive medication adherence and subsequent healthcare utilization and costs. Am J Manag Care 2010; 16:568-76.
8. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366:1545-53.
9. Van Bortel LM, Fici F, Mascagni F. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: A meta-analysis. Am J Cardiovasc Drugs 2008; 8:35-44.
10. Chobanian AV, Bakris GL, Black H.R., Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA 2003; 289:2560-72.
11. Carretero OA, Oparil S. Essential hypertension. Part I: Definition and etiology. Circulation 2000; 101:329-35.
12. Abegunde DO, Mathers CD, Adam T, Ortegon M., Strong K. The burden and costs of chronic diseases in low-income and middle-income countries. Lancet 2007; 370:1929-38.
13. Neal B, MacMahon S, Chapman N. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ace inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials. Blood pressure lowering treatment trialists' collaboration. Lancet 2000; 356:1955-64.
14. Ogden LG, He J, Lydick E., Whelton PK. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the jnc vi risk stratification. Hypertension 2000; 35:539-43.
15. The sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157:2413-46.
16. Chalmers J, Zanchetti A. The 1996 report of a World Health Organization expert committee on hypertension control. J Hypertens 1996; 14:929-33.
17. Chalmers J. Treatment guidelines in hypertension: Current limitations and future solutions. J Hypertens Suppl 1996; 14:S3-8.
18. Chalmers J. Round table 2. First-line drugs: The position of the World Health Organization-International Society of hypertension. J Hypertens Suppl 1993; 11:S381-3.
19. Brehm BR, Bertsch D, von Fallois J, Wolf SC. Beta-blockers of the third generation inhibit endothelin-1 liberation, mrna production and proliferation of human coronary smooth muscle and endothelial cells. J Cardiovasc Pharmacol 2000; 36:S401-3.
20. Dessy C, Saliez J, Ghisdal P., Daneau G, Lobysheva II, Frerart F, Belge C., et al. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. Circulation 2005; 112:1198-205.
21. Ignarro LJ. Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation beta-blocker. Blood Press Suppl 2004; 1:2-16.
22. Kamp O, Sieswerda GT, Visser CA. Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am J Cardiol 2003; 92:344-8.
23. Nodari S, Metra M, Dei Cas L. Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. Nebivolol. Eur J Heart Fail 2003; 5:621-7.
24. Espinola-Klein C, Weisser G, Jagodzinski A., Savvidis S, Warnholtz A, Ostad M.A., et al. Beta-blockers in patients with intermittent claudication and arterial hypertension: Results from the nebivolol or metoprolol in arterial occlusive disease trial. Hypertension 2011; 58:148-54.
25. Uhlíř MF, Havránek K, Lefflerová J, Vojáček J, Widimský J, Winterová KZ. Nebivolol versus metoprolol in the treatment of hypertension. Drug Investig 1991; 3:107-10.